The interpretation of Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update

doi:10.16139/j.1007-9610.2024.05.07

Abstract

Abstract:

Bone-modifying agents (BMAs), including bisphosphonate (BP) and denosumab, can reduce bone-related events caused by breast cancer bone metastasis. “Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update” was published in Journal of Clinical Oncology in January 2022. The new “2022 version Guideline” suggested that the use of BP should be discussed for all postmenopausal patients with early breast cancer who are indicated for adjuvant therapy. Recommended drugs included zoledronate, clodronate, and ibandronate, and the recommended duration of BP was 2-3 years. Owing to the inconsistent results of the ABCSG-18 and D-CARE trials and the lack of data directly comparing denosumab with BP in early breast cancer, the use of denosumab in adjuvant therapy was not recommended. In conclusion, the role of BP in the adjuvant treatment of early breast cancer has been further affirmed, while the value of denosumab remains unclear.

Key words: Breast cancer, Bone-modifying agent(BMA), Bisphosphonates(BP), Adjuvant treatment

CLC Number:

R737.9

LU Yujie, ZHU Siji. The interpretation of Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update[J]. Journal of Surgery Concepts & Practice, 2024, 29(05): 405-408.

References 9

[1]	中国医师协会肿瘤医师分会乳腺癌学组, 中国抗癌协会国际医疗交流分会. 骨改良药物安全性管理专家共识[J]. 中华肿瘤杂志, 2021, 43(6):622-628.
	Breast Cancer Group, Chinese Medical Doctor Association, International Medical Society, Chinese Anti-Cancer Association. Expert consensus on safety management of bone-modifying agents[J]. Chin J Oncol, 2021, 43(6):622-628.
[2]	DHESY-THIND S, FLETCHER G G, BLANCHETTE P S, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer:a cancer care ontario and American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2017, 35(18):2062-2081.
[3]	GNANT M, PFEILER G, STEGER G G, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18):disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(3):339-351.
[4]	COLEMAN R, FINKELSTEIN D M, BARRIOS C, et al. Adjuvant denosumab in early breast cancer (D-CARE):an international, multicentre, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2020, 21(1):60-72.
[5]	GRALOW J R, BARLOW W E, PATERSON A H G, et al. Phase Ⅲ randomized trial of bisphosphonates as adjuvant therapy in breast cancer:S0307[J]. J Natl Cancer Inst, 2020, 112(7):698-707.
[6]	FRIEDL T W P, FEHM T, MÜLLER V, et al. Prognosis of patients with early breast cancer receiving 5 years vs 2 years of adjuvant bisphosphonate treatment:a phase 3 randomized clinical trial[J]. JAMA Oncol, 2021, 7(8):1149-1157.
[7]	EISEN A, SOMERFIELD M R, ACCORDINO M K, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer:ASCO-OH (CCO) guideline update[J]. J Clin Oncol, 2022, 40(7):787-800.
[8]	Predict Breast:NHS PREDICT Tool[EB/OL]. [2024-08-12]. https://breast.predict.nhs.uk/.
[9]	Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer:meta-analyses of individual patient data from randomised trials[J]. Lancet, 2015, 386(10001):1353-1361.

[1]	XU Wangwang^1，2 (徐旺旺), XU Liangfeng^1，2 (许良凤), LIU Ninghui³(刘宁徽), LU Na³(律娜). Histological Image Diagnosis of Breast Cancer Based on Multi-Attention Convolution Neural Network [J]. J Shanghai Jiaotong Univ Sci, 2025, 30(1): 91-106.
[2]	HAO Kun, SUN Yuguang, WANG Rengui, et al. Effect of debulking surgery on upper limb lymphedema after breast cancer surger [J]. Journal of Tissue Engineering and Reconstructive Surgery, 2024, 20(1): 69-.
[3]	ZHANG Fengzhe, TONG Yiwei, CHEN Xiaosong, SHEN Kunwei. Analysis of risk factors for non-sentinel lymph node metastasis in patients with sentinel lymph node-negative breast cancer [J]. Journal of Surgery Concepts & Practice, 2024, 29(05): 409-413.
[4]	HAN Mengyuan, CHEN Xiaosong. Hereditary breast cancer risk gene assessment and counseling: interpretation of NCCN guidelines and Ruijin Hospital clinical practice [J]. Journal of Surgery Concepts & Practice, 2024, 29(05): 401-404.
[5]	DA Qian, RUAN Miao, FEI Xiaochun, WANG Chaofu. Application and research prospects of artificial intelligence in breast cancer pathological diagnosis [J]. Journal of Surgery Concepts & Practice, 2024, 29(05): 389-395.
[6]	CAO Xi, LUO Yongchao, SHEN Songjie. Suitable breast cancer screening strategy for Chinese women [J]. Journal of Surgery Concepts & Practice, 2024, 29(05): 382-388.
[7]	ZHAO Xin, GAO Peng, CHEN Jie. Robotic-assisted surgical systems in treatment of breast cancer: applications and prospects [J]. Journal of Surgery Concepts & Practice, 2024, 29(05): 376-381.
[8]	TANG Xiaolu, HUA Xin, CAO Lu, CHEN Jiayi. Application of 21-Gene test in adjuvant radiotherapy for early breast cancer [J]. Journal of Surgery Concepts & Practice, 2024, 29(03): 270-276.
[9]	OU Dan, CAI Gang, CHEN Jiayi. Bioinformatics analysis for expression of RAD51AP1 in triple negative breast cancer with brain metastasis [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(02): 146-154.
[10]	LIU Juan, YIN Lijuan, FAN Desheng. The clinicopathologic significance of AR, SKP2, SOX10, PD-L1 and TILs expression in triple-negative breast cancer [J]. Journal of Diagnostics Concepts & Practice, 2024, 23(02): 162-172.
[11]	REN Yanxin, YU Yan, XU Kexin, et al. Research progress of the effect of radiotherapy on breast reconstruction with prosthesis and autologous tissue after breast cancer surgery [J]. Journal of Tissue Engineering and Reconstructive Surgery, 2023, 19(5): 511-.
[12]	LI Hui, YIN Yu, LI Chunxiao, et al. Research progress on rehabilitation effect of respiratory training on breast cancer-related lymphedema [J]. Journal of Tissue Engineering and Reconstructive Surgery, 2023, 19(4): 430-.
[13]	ZHU Danli, BAO Wanting, WEI Hao, et al. Advances in breast reconstruction after breast cancer surgery [J]. Journal of Tissue Engineering and Reconstructive Surgery, 2023, 19(2): 201-.
[14]	LI Yuefeng, HONG Jin, LI Zhian, RUAN Guodong, CHEN Weiguo. Prognostic analysis of the patients with HER2-positive breast cancer adjuvant treated with trastuzumab: a report of 1 246 cases [J]. Journal of Surgery Concepts & Practice, 2023, 28(05): 469-476.
[15]	YANG Yi, YANG Xingxia, JIN Sili, ZHANG Xu, ZHU Juanying, CHEN Xiaosong. Clinical application of preoperative MRI examination in breast-conserving surgery for ductal carcinoma in situ [J]. Journal of Surgery Concepts & Practice, 2023, 28(04): 378-382.